Regional tau pathology and loneliness in cognitively normal older adults
- PMID: 30563962
- PMCID: PMC6299114
- DOI: 10.1038/s41398-018-0345-x
Regional tau pathology and loneliness in cognitively normal older adults
Abstract
Loneliness is a perception of social and emotional isolation that increases in prevalence among older adults during the eighth decade of life. Loneliness has been associated with higher brain amyloid-β deposition, a biologic marker of Alzheimer's disease, in cognitively normal older adults, suggesting a link with preclinical Alzheimer's disease pathophysiology. This study examined whether greater loneliness was associated with tau pathology, the other defining feature of Alzheimer's disease, in 117 cognitively normal older adults. Using flortaucipir positron emission tomography, we measured tau pathology in the entorhinal cortex, a region of initial accumulation in aging adults with or without elevated amyloid-β, and in the inferior temporal cortex, a region of early accumulation typically associated with elevated amyloid-β and memory impairment. Loneliness was measured by self-report using the 3-item UCLA-loneliness scale. We found that higher tau pathology in the right entorhinal cortex was associated with greater loneliness, controlling for age, sex, and apolipoprotein E ε4, the Alzheimer's disease genetic risk marker. This association remained significant after further adjustment for socioeconomic status, social network, depression and anxiety scores, and memory performance. There was no association of inferior temporal cortical or left entorhinal tau pathology with loneliness. Exploratory whole-brain surface maps supported these findings and identified additional clusters correlating loneliness and tau in the right fusiform gyrus. These results provide further support for loneliness as a socioemotional symptom in preclinical Alzheimer's disease.
Conflict of interest statement
F.d’O.U., H.I.L.J., K.D.B., and M.R.P. have no disclosures to report. B.J.H. has served as a paid consultant for GE Healthcare. A.P.S. has served as a paid consultant for Biogen and Janssen. D.M.R. has served as a paid consultant for Eli Lilly, Janssen, Biogen and sits on the Scientific Advisory Board for Neurotrack. K.A.J. has served as paid consultant for Abbvie, AZtherapies, Biogen, GE Healthcare, Genetech, Genzyme, Isis, Janssen, Lundbeck, Merck, Novartis, Piramal, Roche, Eli Lilly, and Merck and Siemens Medical Solutions. He has served as a site principal investigator or co-investigator for Biogen, Eisai, Eli Lilly/Avid, Janssen, Lundbeck and Pfizer. R.A.S. has served as a paid consultant for Abbvie, Biogen, Bracket, GE, Genentech, Lundbeck, Merck, Otsuka, Pfizer, Roche and Sanofi. She has served as a co-investigator for Avid, Eli Lilly, and Janssen. She has spoken at symposia sponsored by Biogen, Eli Lilly, and Janssen. N.J.D. has received salary support from Eisai and Eli Lilly. She has served as a paid consultant to Avanir. Her spouse is employed by Alkermes. None of these disclosures are related to the content of this manuscript.
Figures


References
-
- Sperling RA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–292. doi: 10.1016/j.jalz.2011.03.003. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources